The present invention relates to compounds and pharmaceutically acceptable salts of formula (I):
which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.
申请人:The Institutes for Pharmaceutical Discovery, LLC
公开号:EP1620420A2
公开(公告)日:2006-02-01
US7358364B2
申请人:——
公开号:US7358364B2
公开(公告)日:2008-04-15
Substituted carboxylic acids
申请人:Van Zandt C. Michael
公开号:US20060094747A1
公开(公告)日:2006-05-04
The present invention relates to compounds and pharmaceutically acceptable salts of formula I:
which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.